Composite magnetic nano material as well as preparation method and application thereof

By coating the Er3+ doped magnetic body chains of the antibody, the formation of composite magnetic nanomaterials has solved the shortcomings in identification and treatment of existing cancer treatment methods, significantly improved the killing of cancer cells and reduced the normal cells The harm achieved safer and more efficient cancer treatment.

CN119033958APending Publication Date: 2024-11-29ZHEJIANG LAB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411202717.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-06-11
Filing Date
2024-08-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing cancer treatment methods such as surgery, radiotherapy and chemotherapy are difficult to accurately identify cancer cells, resulting in delayed diagnosis and recurrence, and are destructive to normal tissues and cells, and are prone to drug resistance. Targeted anti-cancer drugs have greater side effects. .

Method used

Er3+ doped magnetic body chains produced by the magnetotaxibacterial bacteria AMB-1 are used to modify these magnetic body chains by coating alpha-fetoprotein antibodies or carcinoembryonic antigen antibodies to form composite magnetic nanomaterials for targeting Treat cancer cells.

Benefits of technology

This composite magnetic nanomaterial significantly enhances the cytotoxicity to human liver and breast cancer cells, reduces damage to normal cells, improves therapeutic effects and reduces side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033958A_ABST
    Figure CN119033958A_ABST
Patent Text Reader

Abstract

The invention discloses a composite magnetic nano material as well as a preparation method and application thereof. The composite magnetic nano material is a magnetosome chain which is coated with an alpha fetoprotein antibody or a carcino-embryonic antigen antibody and is doped with Er < 3 + > generated by magnetotactic bacteria. The Er < 3 + >-doped magnetosome chain which is coated by the alpha fetoprotein antibody or the carcino-embryonic antigen antibody and is generated by the magnetotactic bacteria can be used for treating cancers.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a composite magnetic nanomaterial and a preparation method and application thereof. Background Art

[0002] Cancer is an important disease that affects human health. It is often treated clinically with surgical resection, radiotherapy, chemotherapy and other methods. However, there are still problems such as cancer tissues are difficult to identify and proto-cancer cells are easy to metastasize, which leads to late diagnosis and easy recurrence after surgery. Chemotherapy and radiotherapy methods also have obvious lethality to normal tissues and cells while treating them, and are prone to drug resistance. Therefore, targeted anti-cancer and reducing drug side effects are important means of cancer treatment.

[0003] In recent years, with the continuous development of nanotechnology, the application of nanomaterials in the biomedical field has made great progress. Nanomaterials have better therapeutic effects in the fight against malignant tumors due to their nanoscale size, high specific surface area, and surface modifiability.

[0004] Magnetotactic bacteria can form membrane-coated magnetic nanoparticles, magnetosomes, through biomineralization in vivo. Compared with artificially synthesized magnetic nanoparticles, magnetosomes have excellent properties such as uniform morphology and size, single magnetic domain, easy modification of the outer biofilm, and good biological compatibility. In addition, the magnetosomes in magnetotactic bacteria will assemble to form magnetosome chains. The assembled magnetosome chains have the synergistic magnetic effect of a single nanoparticle, which can enhance the function of magnetic nanoparticles. Although magnetosome chains have excellent performance, they must be further modified and improved to achieve more functional combinations, thereby enhancing the therapeutic effect of magnetosome chains in anti-cancer. Summary of the invention

[0005] The purpose of the present invention is to provide a composite magnetic nanomaterial and a preparation method and application thereof.

[0006] One object of the present invention is to provide a composite magnetic nanomaterial, wherein the composite magnetic nanomaterial is Er produced by magnetotactic bacteria and coated with alpha-fetoprotein antibody or carcinoembryonic antigen antibody. 3+ Doped magnetosome chains.

[0007] In some embodiments, the magnetotactic bacteria is magnetotactic bacteria AMB-1 ATCC 700264.

[0008] Another object of the present invention is to provide a method for preparing a composite magnetic nanomaterial, the method comprising:

[0009] Magnetotactic bacteria were grown in standard medium for growing magnetotactic bacteria;

[0010] Then in the presence of Er3+ Cultivating the magnetotactic bacteria in a standard culture medium for culturing magnetotactic bacteria;

[0011] In the magnetotactic bacteria, Er is synthesized 3+ After the magnetosome chains were doped, the cells were broken to obtain Er 3+ Doped magnetosome chains;

[0012] AFP antibody or CEA antibody is added to the suspension of the Er 3+ doped magnetosome chain, and the suspension is incubated to obtain Er produced by magnetotactic bacteria coated with AFP antibody or CEA antibody. 3+ Doped magnetosome chains.

[0013] In some embodiments, the magnetotactic bacteria is magnetotactic bacteria AMB-1 ATCC 700264.

[0014] In some embodiments, the 3+ The standard culture medium for culturing magnetotactic bacteria contains 200 μM ErCl3·6H2O.

[0015] In some embodiments, the standard culture medium for culturing magnetotactic bacteria contains 0.2 mM iron ions.

[0016] The Er produced by magnetotactic bacteria coated with alpha-fetoprotein antibody or carcinoembryonic antigen antibody of the present invention 3+ Doped magnetosome chains can be used to treat cancer.

[0017] In some embodiments, the Er coated with alpha-fetoprotein antibody 3+ The doped magnetosome chains have cytotoxicity against human hepatoma cell HepG2 cells.

[0018] In some embodiments, the carcinoembryonic antigen antibody-coated Er 3+ The doped magnetosome chains have cytotoxicity against human breast cancer Hela cells.

[0019] Another object of the present invention is to provide a drug for treating cancer, the drug comprising as an active ingredient an alpha-fetoprotein antibody or a carcinoembryonic antigen antibody-coated Er produced by magnetotactic bacteria. 3+ Doped magnetosome chains. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 An electron micrograph of the magnetotactic bacterium AMB-1 after 48 hours of cultivation is shown.

[0021] Figure 2 Figure 2 shows the formation of Er3 in the magnetotactic bacteria AMB-1 characterized by transmission electron microscopy (EDS). +Results of doped magnetosome chains.

[0022] Figure 3 The morphological features of the magnetosome chain (a) and the magnetosome chain coated with alpha-fetoprotein antibody (AFP antibody) (b) characterized by transmission electron microscopy are shown.

[0023] Figure 4 The results of the cell activity experiment characterizing the effect of composite magnetosomes on the activity of liver cancer cells HepG2 are shown. DETAILED DESCRIPTION

[0024] In order to better illustrate the purpose, complete technical route and advantages of the present invention, the present invention will be further described in detail below in conjunction with specific embodiments and drawings. However, the embodiments described below are only part of the embodiments of the present invention and do not include all the embodiments. Based on the embodiments of the present invention, other embodiments that can be obtained by those skilled in the art without paying creative work all belong to the protection scope of the present invention.

[0025] In the embodiments described below, unless otherwise specified, the conventional methods used are technical means generally recognized or commonly used by those skilled in the art, and the instruments, reagents, consumables, etc. used in the embodiments of the present invention can be obtained through regular commercial channels.

[0026] Embodiment 1,

[0027] Composite magnetosome chain-Er coated with alpha-fetoprotein antibody (Bioss) 3+ Doped magnetosome chains

[0028] A standard medium for magnetotactic bacteria AMB-1 was prepared according to the ATCC formula, in which the iron ion content was 0.2 mM. The magnetotactic bacteria AMB-1 (purchased from ATCC, strain number ATCC700264) was cultured in the standard medium for 24 hours, the original standard medium was removed by centrifugation, and the AMB-1 bacteria were cultured in a medium containing 200 μM ErCl3·6H2O and continued to be cultured under microaerobic conditions for 48 hours. Then, a fluorescence spectrometer (Agilent, Cary Eclipse fluorescence spectrometer) was used to measure the synthesis of Er by the bacteria. 3+ The luminescence performance of the doped magnetosomes was measured. The bacteria were placed in a cuvette, the bacterial suspension was excited with 970nm excitation light, and the emission spectrum at a wavelength of 520-570nm was recorded.

[0029] Figure 1 An electron micrograph of the magnetotactic bacterium AMB-1 after 48 hours of cultivation is shown. Figure 2 Figure 2 shows the formation of Er3 in the magnetotactic bacteria AMB-1 characterized by transmission electron microscopy (EDS). + Results of doped magnetosome chains.

[0030] like Figure 1 and Figure 2 As shown, 3+ Successfully doped into the magnetosome chains formed by magnetotactic bacteria.

[0031] The magnetotactic bacteria were enriched and suspended in 10 mM HEPES buffer (pH 7.4), and then the magnetotactic bacterial suspension was placed in a cell ultrasonic disruptor, ultrasonicated for 30 minutes under freezing conditions, and centrifuged to separate the ultrasonicated bacterial fragments and magnetosome chains. After repeating the ultrasonication and centrifugation three times, Er 3+ The doped magnetosome chains were suspended in 10 mM phosphate buffer.

[0032] Add 200 μM alpha-fetoprotein antibody to 5 mL of magnetosome chain suspension, mix well, incubate at 4 °C for 2 hours, centrifuge to discard excess antibody in the supernatant, and wash twice with 10 mM phosphate buffer to obtain alpha-fetoprotein antibody-coated Er 3+ Doped magnetosome chains.

[0033] Figure 3 The morphological characteristics of the magnetosome chain (a) and the magnetosome chain coated with alpha-fetoprotein antibody (AFP antibody) (b) characterized by transmission electron microscopy are shown. It can be seen that a layer of obvious antibody molecule traces appears on the surface of the magnetosome chain coated with alpha-fetoprotein antibody (AFP antibody), and the magnetosome particle size becomes larger, indicating that the surface of the magnetosome chain is successfully coated with AFP antibody.

[0034] Anti-liver cancer cell validation experiment:

[0035] Human hepatoma cell HepG2 (Jin Shaoyuan Biotechnology) was cultured in DMEM medium containing 15% fetal bovine serum at 37°C and 5% CO2. When the cell growth density in the cell culture flask reached 80%, the cells were digested with 0.2% trypsin for 1 minute and the cell density was 2×10 5HepG2 cells were transferred to a 96-well plate and cultured at 100 μL / mL and 100 μL / well. After 24 hours of cell culture, the cell supernatant culture medium was removed, and culture medium containing 10 μg / mL and 20 μg / mL of composite magnetosome chains were added to the wells of the two experimental groups, respectively, and incubated with the cells for 12 hours. A blank control group with only culture medium added and a magnetosome treatment group with 10 μg / mL magnetosome chains added were also set up. After incubation, the cells were irradiated with 970 nm light under a fluorescence microscope (Nikon), and fluorescence imaging at 557 nm was observed to determine the absorption of magnetosome chains by HepG2 cells. Then, the two experimental groups with composite magnetosome chains were placed in an axial magnetic field for 5 minutes for magnetic thermal treatment. Next, 10 μL of CCK-8 reagent (Biyuntian, CCK-8 kit) was added to each well, and the cells were incubated for 2 to 4 hours. The absorbance of each well was measured at 450 nm using an ELISA reader to detect the activity of each group of HepG2 cells.

[0036] The experimental groups using 10 μg / mL and 20 μg / mL composite magnetosome chains were cytotoxic to human liver cancer cell HepG2 cells. The cytotoxicity of the experimental group using 20 μg / mL composite magnetosome chains was significantly stronger than that of the experimental group using 10 μg / mL composite magnetosome chains.

[0037] Embodiment 2,

[0038] Composite magnetosome chain-Er coated with carcinoembryonic antigen antibody (Bioss) 3+ Doped magnetosome chains

[0039] A standard medium for magnetotactic bacteria AMB-1 was prepared according to the ATCC formula, in which the iron ion content was 0.2 mM. The magnetotactic bacteria AMB-1 (purchased from ATCC, strain number ATCC700264) was cultured in the standard medium for 24 hours, the original standard medium was removed by centrifugation, and the AMB-1 bacteria were cultured in a medium containing 200 μM ErCl3·6H2O and continued to be cultured under microaerobic conditions for 48 hours. Then, a fluorescence spectrometer (Agilent, Cary Eclipse fluorescence spectrometer) was used to measure the bacterial synthesis of Er. 3+ The luminescence performance of the doped magnetosomes was measured. The bacteria were placed in a cuvette, the bacterial suspension was excited with 970nm excitation light, and the emission spectrum at a wavelength of 520-570nm was recorded.

[0040] The magnetotactic bacteria were enriched and suspended in 10 mM HEPES buffer (pH 7.4), and then the magnetotactic bacterial suspension was placed in a cell ultrasonic disruptor, ultrasonicated for 30 minutes under freezing conditions, and centrifuged to separate the ultrasonicated bacterial fragments and magnetosome chains. After repeating the ultrasonication and centrifugation three times, Er 3+The doped magnetosome chains were suspended in 10 mM phosphate buffer.

[0041] Add 200 μM carcinoembryonic antigen antibody to 5 mL of magnetosome chain suspension, mix well, incubate at 4 °C for 2 hours, centrifuge to discard excess antibody in the supernatant, and wash twice with 10 mM phosphate buffer to obtain carcinoembryonic antigen antibody-coated Er 3+ Doped magnetosome chains.

[0042] Anti-breast cancer cell validation experiment:

[0043] Human breast cancer Hela cells (Jin Shaoyuan Biotechnology) were cultured in DMEM medium containing 15% fetal bovine serum at 37°C and 5% CO2. When the cell growth density in the cell culture flask reached 80%, they were digested with 0.2% trypsin for 1 minute and the cell density was 2×10 5 / mL, 100μL / well Hela cells were transferred to a 96-well plate for culture. After 24 hours of cell culture, the cell supernatant culture medium was removed, and the culture medium containing 20μg / mL composite magnetosome chains was added to the wells of the two experimental groups, and the cells were incubated for 12 hours. A blank control group with only culture medium added was also set up. After the incubation was completed, the cells were irradiated with 970nm light under a fluorescence microscope (Nikon), and the fluorescence imaging at 557nm was observed to determine the absorption of magnetosome chains by Hela cells. Then, in the two experimental groups with magnetosome chains added, one group was not heated under magnetic field conditions, and the other group was placed in an axial magnetic field for 5 minutes for magnetic heat treatment. Then, 10μL CCK-8 reagent (Biyuntian, CCK-8 kit) was added to each well, and the cells were incubated for 2 to 4 hours. The absorbance of each well was measured at 450nm using an enzyme reader to detect the cell activity of Hela cells.

[0044] Er3+-doped magnetosome chains coated with carcinoembryonic antigen antibody are cytotoxic to human breast cancer Hela cells.

[0045] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.

Claims

1. A composite magnetic nanomaterial, characterized in that: The composite magnetic nanomaterial is Er produced by magnetotactic bacteria and coated with alpha-fetoprotein antibody or carcinoembryonic antigen antibody. 3+ Doped magnetosome chains.

2. The nanomaterial according to claim 1, characterized in that The magnetotactic bacteria is the magnetotactic bacteria AMB-1ATCC700264.

3. A method for preparing a composite magnetic nanomaterial, characterized in that: The method comprises: Magnetotactic bacteria were grown in standard medium for growing magnetotactic bacteria; Then in the presence of Er 3+ Cultivating the magnetotactic bacteria in a standard culture medium for culturing magnetotactic bacteria; In the magnetotactic bacteria, Er is synthesized 3+ After the magnetosome chains were doped, the cells were broken to obtain Er 3+ Doped magnetosome chains; To the said Er 3+ AFP antibody or CEA antibody is added to the suspension of the doped magnetosome chain, and the suspension is incubated statically to obtain Er produced by magnetotactic bacteria coated with AFP antibody or CEA antibody. 3+ Doped magnetosome chains.

4. The method according to claim 3, characterized in that The magnetotactic bacteria is the magnetotactic bacteria AMB-1ATCC700264.

5. The method according to claim 4, characterized in that The Er 3+ The standard culture medium for culturing magnetotactic bacteria contains 200 μM ErCl3·6H2O.

6. The Er produced by magnetotactic bacteria coated with alpha-fetoprotein antibody or carcinoembryonic antigen antibody according to claim 1 or 2 3+ Application of doped magnetosome chains in the preparation of drugs for treating cancer.

7. The use according to claim 6, characterized in that: The alpha-fetoprotein antibody-coated Er 3+ Doped magnetosome chains for the treatment of liver cancer.

8. The use according to claim 6, characterized in that: The carcinoembryonic antigen antibody-coated Er 3+ Doped magnetosome chains for the treatment of human breast cancer.

9. A drug for treating cancer, characterized in that: The drug comprises as an active ingredient the Er produced by magnetotactic bacteria coated with the alpha-fetoprotein antibody or carcinoembryonic antigen antibody according to claim 1 or 2. 3+ Doped magnetosome chains.

10. The drug according to claim 9, characterized in that The cancer is liver cancer or human breast cancer.